Drug resistance

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Retrieved on: 
Saturday, December 9, 2023

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.
  • The new preclinical data covers results for SC-2882, Scenic’s first-in-class QPCTL inhibitor, as a potential new treatment approach for diffuse large B-cell lymphoma (DLBCL).
  • SC-2882 targets QPCTL and thereby inhibits the CD47-SIRPα “don’t eat me” checkpoint and lowers immune suppression in the tumor microenvironment.
  • Analysis of DLBCL patient datasets revealed that QPCTL expression negatively correlates with overall and progression-free survival.

Thermo Fisher Scientific and Project HOPE Partner to Advance Health Equity Among HIV Positive Youth in Sub-Saharan Africa

Retrieved on: 
Friday, December 1, 2023

The partnership greatly advances Project HOPE’s efforts in Northwestern Nigeria by expanding access to critical community HIV testing services.

Key Points: 
  • The partnership greatly advances Project HOPE’s efforts in Northwestern Nigeria by expanding access to critical community HIV testing services.
  • Additionally, Thermo Fisher will engage its employees in volunteer opportunities to augment the services delivered by Project HOPE.
  • “Project HOPE is delighted to collaborate with Thermo Fisher Scientific on this transformative journey to improve the lives of adolescents and young persons in Northwestern Nigeria,” said Dr. Uche RalphOpara, deputy chief health officer, Project HOPE.
  • To learn more about Thermo Fisher’s global commitment to health equity, explore the company’s Corporate Social Responsibility Report .

TOLREMO Treats First Patient in Phase I Trial with TT125-802, a Novel Therapeutic Agent to Overcome Transcriptional Cancer Drug Resistance

Retrieved on: 
Tuesday, November 28, 2023

TT125-802 is an orally available small molecule CBP/p300 bromodomain inhibitor designed to prevent non-genetic cancer drug resistance and thereby improve the response rates and durability of targeted cancer treatments.

Key Points: 
  • TT125-802 is an orally available small molecule CBP/p300 bromodomain inhibitor designed to prevent non-genetic cancer drug resistance and thereby improve the response rates and durability of targeted cancer treatments.
  • In preclinical testing, the compound has demonstrated the ability to block critical transcriptional resistance pathways responsible for cancer’s earliest escape mechanisms to targeted therapies.
  • "Initiating our Phase 1 clinical trial is an important corporate milestone for TOLREMO.
  • “We are deeply committed to overcoming transcriptionally mediated cancer drug resistance for patient benefit, and this trial marks the start of an exciting new phase for the company.”
    The Phase I dose-escalation study will enroll patients across a range of solid tumor indications.

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics

Retrieved on: 
Wednesday, December 13, 2023

"We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.

Key Points: 
  • "We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.
  • "It's such an honor to be a recipient of the Astellas Future Innovator Prize, which will further support TippingPoint's research," said Laura Hsieh, CEO of TippingPoint Biosciences.
  • "Astellas' deep industry expertise coupled with MBC BioLabs' resources will play integral roles in accelerating our drug discovery development and successfully implementing TippingPoint's programs.
  • Both TippingPoint Biosciences and Altay Therapeutics will reside at MBC BioLabs with the next year sponsored by Astellas.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

Retrieved on: 
Wednesday, November 29, 2023

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ -- USA News Group  -  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that's happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers. Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer. Among the top developers putting out promising results with new treatments are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eli Lilly and Company (NYSE:LLY), and POINT Biopharma Global Inc. (NASDAQ:PNT).

Key Points: 
  • Perhaps the most concerning are the incidences of pancreatic cancer, which while only being the 4th most common cause of death, remains one of the lowest survival rates among all cancers.
  • Despite the dire odds, several biotech developers are working diligently to find treatments to enhance the chances of those who've been unlucky enough to contract pancreatic cancer.
  • Late last year, favourable data from trials involving pelareorep in treating pancreatic cancer led to the FDA rewarding it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • By mid-2023, the Pancreatic Cancer Action Network (PanCAN) selected pelareorep for their pivotal Phase 3 trial , called Precision Promise.

Halia Therapeutics to Present New Preclinical Data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Monday, November 27, 2023

ASH is one of the largest gatherings of the international hematology community, bringing together experts in the field to discuss the latest research in pathogenesis and clinical treatment of hematologic diseases.

Key Points: 
  • ASH is one of the largest gatherings of the international hematology community, bringing together experts in the field to discuss the latest research in pathogenesis and clinical treatment of hematologic diseases.
  • Halia will present a company showcase, which will provide an overview of the company's mission, values, and therapeutics currently in development for chronic inflammatory and neurological diseases targeting the NLRP3 inflammasome.
  • "We are delighted to showcase our company and highlight the importance of our novel approach in targeting the NLRP3 inflammasome.
  • Presenter: David Bearss, Ph.D., CEO of Halia Therapeutics and Alan List, MD, Halia Therapeutics
    Session Name: 604.

Magnolia Medical Technologies Marks World AMR Awareness Week by Recognizing the Need to Reduce Antibiotic Usage through Accurate Blood Culture Results

Retrieved on: 
Monday, November 20, 2023

SEATTLE, Nov. 20, 2023 /PRNewswire/ -- In observance of World AMR Awareness Week (WAAW), Magnolia Medical Technologies, Inc., the inventors of the Steripath® Initial Specimen Diversion Device® (ISDD®) and the ISDD market to prevent false-positive sepsis tests, is driving efforts to highlight the role of diagnostic stewardship in combating the risk of AMR.

Key Points: 
  • Accurate blood culture results prevent patients from receiving unnecessary, prolonged, and potentially harmful antibiotic therapies, and associated preventable clinical complications, including acute kidney injury, Clostridioides difficile infection (CDI), and multidrug-resistant organism (MDRO) infections.
  • We recently completed a survey of over 1,000 Americans that highlighted the public and medical community's concern with the issue of AMR."
  • Magnolia Medical is encouraging everyone to "Go Blue" from November 18 to 24 to raise awareness for AMR and the need for continued education of this issue.
  • Please visit VoicesofSepsis.org to encourage action from your congressional representatives to support patient safety measures that also help combat the threat of AMR.

Cancer therapy shows promise against tuberculosis

Retrieved on: 
Thursday, November 16, 2023

SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).

Key Points: 
  • SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).
  • - Larry Schlesinger, MD
    Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.
  • The therapy evaluated in this study combines two molecules – one is already FDA-approved for cancer patients, and the other is in Phase 1/2 clinical trials for cancer.
  • That's the power of a host-directed therapy targeting the human's immune response versus trying to attack the pathogen directly."

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

Retrieved on: 
Wednesday, November 15, 2023

NEW YORK, Nov. 15, 2023 /PRNewswire-PRWeb/ -- The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

Key Points: 
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • "Cancer target discovery research has traditionally concentrated on pinpointing genes that facilitate cancer cell growth and survival.
  • It allows them to see how cancer genes affect not only cancer cells but also the immune system within tumors.